The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling

Journal of Clinical Investigation

Volumn 122, Issue 10, 2012, Pages 3579-3592

  Su, Xinming ^a   Floyd, Desiree H ^a   Hughes, Alun ^b   Xiang, Jingyu ^a   Schneider, Jochen G ^a,c,d   Uluckan, Ozge ^a   Heller, Emanuela ^a   Deng, Hongju ^a   Zou, Wei ^e   Craft, Clarissa S ^f   Wu, Kaiming ^a   Hirbe, Angela C ^a   Grabowska, Dorota ^f   Eagleton, Mark C ^a   Townsley, Sarah ^a   Collins, Lynne ^f   Piwnica Worms, David ^f   Steinberg, Thomas H ^f   Novack, Deborah V ^e   Conley, Pamela B ^g   Hurchla, Michelle A ^a   Rogers, Michael ^b   Weilbaecher, Katherine N ^a   more..

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^d SAARLAND UNIVERSITY   (Germany)

^e Division of Bone and Mineral Diseases   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Portola Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CLOPIDOGREL; OSTEOCLAST DIFFERENTIATION FACTOR; PURINERGIC P2Y RECEPTOR; RAP1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE REMODELING; CELL ADHESION; CELL FUNCTION; CONTROLLED STUDY; FEMALE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE; TUMOR GROWTH;

ADENOSINE DIPHOSPHATE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CARCINOMA; CELL ADHESION; CELLS, CULTURED; ENZYME ACTIVATION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RAP1 GTP-BINDING PROTEINS; RECEPTORS, PURINERGIC P2Y12; SPECIFIC PATHOGEN-FREE ORGANISMS; TICLOPIDINE;

EID: 84867183289     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38576     Document Type: Article

References (80)

1. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504-1508.
2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411-425.
3. Orriss I, et al. Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed). 2011;3:1038-1046.
4. Reyes JP, Sims SM, Dixon SJ. P2 receptor expression, signaling and function in osteoclasts. Front Biosci (Schol Ed). 2011;3:1101-1118.
5. Korcok J, Raimundo LN, Du X, Sims SM, Dixon SJ. P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. J Biol Chem. 2005;280(17):16909-16915. (Pubitemid 41389150)
6. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Bone. 2002;31(5):582-590. (Pubitemid 35449700)
7. Orriss IR, et al. Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology. 2007;148(9):4208-4216. (Pubitemid 47295696)
8. Hoebertz A, Meghji S, Burnstock G, Arnett TR. Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. FASEB J. 2001;15(7):1139-1148. (Pubitemid 32436299)
9. Hollopeter G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202-207. (Pubitemid 32144286)
10. Andre P, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112(3):398-406. (Pubitemid 38063768)
11. Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003;3(2):113-122.
12. Bernardi B, et al. The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIbbeta3. Blood. 2006;107(7):2728-2735.
13. Bertoni A, et al. Relationships between Rap1b, affinity modulation of integrin alpha IIb-beta 3, and the actin cytoskeleton. J Biol Chem. 2002;277(28):25715-25721. (Pubitemid 34951891)
14. Kamae T, et al. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb) beta3 activation: association with Rap1B activation. J Thromb Haemost. 2006;4(6):1379-1387.
15. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem. 2004;279(6):4186-4195. (Pubitemid 38199005)
16. Larson MK, et al. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood. 2003;101(4):1409-1415. (Pubitemid 36182513)
17. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. J Biol Chem. 2002;277(26):23382-23390. (Pubitemid 34952169)
18. Lorenowicz MJ, van GJ, de BM, Hordijk PL, Fernandez-Borja M. Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxis. J Leukoc Biol. 2006;80(6):1542-1552. (Pubitemid 44904993)
19. Lorenowicz MJ, Fernandez-Borja M, Kooistra MR, Bos JL, Hordijk PL. PKA and Epac1 regulate endothelial integrity and migration through parallel and independent pathways. Eur J Cell Biol. 2008;87(10):779-792.
20. Medeiros RB, et al. Protein kinase D1 and the beta 1 integrin cytoplasmic domain control beta 1 integrin function via regulation of Rap1 activation. Immunity. 2005;23(2):213-226. (Pubitemid 41169290)
21. Feng X, et al. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest. 2001;107(9):1137-1144. (Pubitemid 32422910)
22. Bakewell SJ, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003;100(24):14205-14210. (Pubitemid 37499215)
23. Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin. J Cell Biol. 2003;162(3):499-509. (Pubitemid 36988558)
24. Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005;208:88-105. (Pubitemid 41746387)
25. Zhao H, Kitaura H, Sands MS, Ross FP, Teitelbaum SL, Novack DV. Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res. 2005;20(12):2116-2123. (Pubitemid 41698775)
26. Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S. Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia. 2007;55(6):604-616. (Pubitemid 46474302)
27. Simon J, et al. Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem. 2002;277(35):31390-31400. (Pubitemid 34968938)
28. Tolhurst G, Vial C, Leon C, Gachet C, Evans RJ, Mahaut-Smith MP. Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood. 2005;106(5):1644-1651. (Pubitemid 41208577)
29. Krzeminski P, Suplat D, Czajkowski R, Pomorski P, Baranska J. Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells. FEBS J. 2007;274(8):1970-1982. (Pubitemid 46587997)
30. Mamedova LK, Gao ZG, Jacobson KA. Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Biochem Pharmacol. 2006;72(8):1031-1041. (Pubitemid 44374463)
31. Haynes SE, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006;9(12):1512-1519. (Pubitemid 44862659)
32. Myrtek D, et al. Activation of human alveolar macrophages via P2 receptors: coupling to intracellular Ca2+ increases and cytokine secretion. J Immunol. 2008;181(3):2181-2188.
33. Pausch MH, Lai M, Tseng E, Paulsen J, Bates B, Kwak S. Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae. Biochem Biophys Res Commun. 2004;324(1):171-177. (Pubitemid 39328083)
34. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med. 2010;207(9):1807-1817.
35. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11(3):201-212.
36. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di VF. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008;3(7):e2599.
37. Moreira PI, Santos MS, Moreno AM, Seica R, Oliveira CR. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes. 2003;52(6):1449-1456. (Pubitemid 36666200)
38. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-832.
39. Honda S, et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci. 2001;21(6):1975-1982. (Pubitemid 32221381)
40. Kurpius D, Nolley EP, Dailey ME. Purines induce directed migration and rapid homing of microglia to injured pyramidal neurons in developing hippocampus. Glia. 2007;55(8):873-884. (Pubitemid 46787197)
41. Marcinek DJ, Schenkman KA, Ciesielski WA, Lee D, Conley KE. Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle. J Physiol. 2005;569(pt 2):467-473. (Pubitemid 41830115)
42. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol. 2007;292(2):C670-C686.
43. Ryan LM, Rachow JW, McCarty DJ. Synovial fluid ATP: a potential substrate for the production of inorganic pyrophosphate. J Rheumatol. 1991;18(5):716-720.
44. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol. 2003;64(5):1210-1216. (Pubitemid 37310754)
45. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340-345. (Pubitemid 38544175)
46. Kronlage M, et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal. 2010;3(132):ra55.
47. McHugh KP, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105(4):433-440. (Pubitemid 30127243)
48. Falker K, Lange D, Presek P. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets. Thromb Haemost. 2005;93(5):880-888. (Pubitemid 40691545)
49. Kauffenstein G, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin - a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 2001;505(2):281-290. (Pubitemid 32896681)
50. Gao L, et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res. 2006;66(16):7880-7888. (Pubitemid 44299150)
51. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest. 2003;111(5):749-758. (Pubitemid 36278593)
52. Bradley EW, Ruan MM, Vrable A, Oursler MJ. Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival. J Cell Biochem. 2008;104(4):1439-1451. (Pubitemid 351961713)
53. Korganow AS, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999;10(4):451-461.
54. Savi P, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103(29):11069-11074. (Pubitemid 44148419)
55. Smyth SS, Tsakiris DA, Scudder LE, Coller BS. Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): studies using monoclonal antibodies and beta3-null mice. Thromb Haemost. 2000;84(6):1103-1108. (Pubitemid 32014048)
56. Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol. 2008;3:457-484. (Pubitemid 351488289)
57. De Simone R, Niturad CE, De Nuccio C, Ajmone-Cat MA, Visentin S, Minghetti L. TGF-beta and LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression. J Neurochem. 2010;115(2):450-459.
58. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005;115(3):680-687. (Pubitemid 40322242)
59. Chrzanowska-Wodnicka M, Kraus AE, Gale D, White GC, Vansluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood. 2008;111(5):2647-2656.
60. Dorsam RT, Kim S, Jin J, Kunapuli SP. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem. 2002;277(49):47588-47595. (Pubitemid 36159279)
61. Irino Y, Nakamura Y, Inoue K, Kohsaka S, Ohsawa K. Akt activation is involved in P2Y12 receptor-mediated chemotaxis of microglia. J Neurosci Res. 2008;86(7):1511-1519. (Pubitemid 351642444)
62. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest. 2001;108(3):477-483. (Pubitemid 32730794)
63. Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases. 2011;2(3):117-130.
64. Ito Y, et al. Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization. J Clin Invest. 2010;120(6):1981-1993.
65. Iyu D, et al. Mode of action of P2Y(12) antagonists as inhibitors of platelet function. Thromb Haemost. 2011;105(1):96-106.
66. Jackson SW, et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Ent-pd1-null mice. Am J Pathol. 2007;171(4):1395-1404. (Pubitemid 47582911)
67. Uluckan O, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem. 2008;104(4):1311-1323. (Pubitemid 351961703)
68. Winning J, Claus RA, Pletz MW, Bauer M, Losche W. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011;36(3):317-318.
69. Reynolds LE, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8(1):27-34. (Pubitemid 34101725)
70. Robinson SD, Hodivala-Dilke KM. The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol. 2011;23(5):630-637.
71. Suva LJ, et al. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol. 2008;172(2):430-439. (Pubitemid 351282030)
72. Morgan EA, et al. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J. 2010;24(4):1117-1127.
73. Vestergaard P, Steinberg TH, Schwarz P, Jørgensen NR. Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture [published online ahead of print April 2, 2011]. Int J Cardiol. doi:10.1016/j.ijcard.2011.03.026.
74. Michelson AD. New P2Y12 antagonists. Curr Opin Hematol. 2009;16(5):371-377.
75. Hodivala-Dilke KM, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238. (Pubitemid 29053141)
76. Léon C, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999;104(12):1731-1737. (Pubitemid 30053190)
77. Uluckan O, et al. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res. 2009;69(7):3196-3204.
78. Smith MC, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64(23):8604-8612. (Pubitemid 39552073)
79. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods. 2005;2(8):607-614. (Pubitemid 41086852)
80. Lai CF, et al. Accentuated ovariectomy-induced bone loss and altered osteogenesis in heterozygous N-cadherin null mice. J Bone Miner Res. 2006;21(12):1897-1906.